Holmberg, Carl-Jacob
Mikiver, Rasmus
Isaksson, Karolin
Ingvar, Christian
Moncrieff, Marc
Nielsen, Kari
Ny, Lars
Lyth, Johan
Olofsson Bagge, Roger http://orcid.org/0000-0001-5795-0355
Funding for this research was provided by:
The Krapperup foundation
Knut och Alice Wallenbergs Stiftelse
Mats Paulsson Trust
ALF-agreement of Sweden
The Welander Finsen foundation
The S.R Gorthon foundation
University of Gothenburg
Article History
Received: 23 June 2022
Accepted: 12 June 2023
First Online: 14 August 2023
Disclosure
: Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx as well as speaker honoraria from Roche and Pfizer, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche, and Sanofi Genzyme. Lars Ny has received institutional research grants from Merck and Syndax Pharmaceuticals as well as speaker honoraria from BMS, Johnson&Johnson, Leo Pharma, MSD, Novartis, and Pfizer, and has served on advisory boards for BMS, MSD, Novartis, Pierre Fabre, Sanofi Genzyme, and Zealth (Immunocore). Kari Nielsen has received speaker honoraria from UCB Pharma, LEO pharma, Novartis Sweden, and Galderma Sweden, and has served on an advisory board for MSD. Karolin Isaksson has received speaker honoraria from Pierre Fabre. The remaining authors have no conflicts of interests.